Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Robert W RobeySusan E Bates

Abstract

The increased expression of markers associated with a differentiated phenotype, such as P-glycoprotein (Pgp), follows treatment with histone deacetylase inhibitors. Because depsipeptide (FR901228, FK228, NSC630176) is a substrate for Pgp, up-regulation of the gene that encodes it, MDR1, would mean that depsipeptide induces its own mechanism of resistance. To examine the effect of depsipeptide on expression of ATP-binding cassette transporters associated with multidrug resistance, the kidney cancer cell lines 108, 121, 127, and 143 were treated with depsipeptide and evaluated by quantitative reverse transcription-PCR. Increased levels of MDR1 (1.3- to 6.3-fold) and ABCG2 (3.2- to 11.1-fold) but not MRP1 (0.9- to 1.3-fold) were observed. The induced Pgp transported the fluorescent substrates rhodamine 123, bisantrene, calcein-AM, BODIPY-vinblastine, and BODIPY-paclitaxel. In normal peripheral blood mononuclear cells (PBMC) and circulating tumor cells obtained from patients receiving depsipeptide, increased levels of histone H3 acetylation were found. We next examined MDR1 levels in normal and malignant PBMCs obtained from 15 patients enrolled in clinical trials with depsipeptide and detected up to a 6-fold increase in normal PBMC...Continue Reading

References

Nov 11, 1991·International Journal of Cancer. Journal International Du Cancer·G M LaiS E Bates
Jul 4, 1990·Journal of the National Cancer Institute·P SkehanM R Boyd
Feb 1, 1995·Journal of Bioenergetics and Biomembranes·U A GermannM M Gottesman
Jan 7, 1999·Breast Cancer Research and Treatment·G RajgolikarH C Wang
Jun 24, 1999·The Journal of Urology·E GamelinS E Bates
Sep 29, 1999·Advances in Experimental Medicine and Biology·C W van HaselenW A van Vloten
Oct 8, 1999·British Journal of Pharmacology·C MartinR Callaghan
Aug 3, 2000·Journal of the National Cancer Institute·P A MarksR A Rifkind
Oct 19, 2000·Cancer Investigation·A P JillellaD L Cooper
Nov 28, 2000·Japanese Journal of Cancer Research : Gann·M MurataT Naoe
Oct 24, 2001·Current Opinion in Oncology·P A MarksR A Rifkind
Mar 21, 2002·Nature Reviews. Cancer·P MarksW K Kelly
Mar 21, 2002·Nature Reviews. Cancer·Michael M GottesmanSusan E Bates
Jun 18, 2002·Molecular Pharmacology·Chava Kimchi-SarfatyMichael M Gottesman
Jul 29, 2004·Current Pharmaceutical Design·Richard Piekarz, Susan Bates
Jan 7, 2005·The Journal of Pharmacology and Experimental Therapeutics·Jim J XiaoKenneth K Chan
Apr 27, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Qin C RyanEdward A Sausville
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Kevin KellyVictoria M Richon

❮ Previous
Next ❯

Citations

Mar 12, 2013·International Journal of Hematology·Teru Hideshima, Kenneth C Anderson
Sep 9, 2011·Molecular Pharmaceutics·Robert W RobeySusan E Bates
Feb 22, 2008·The Journal of Pharmacology and Experimental Therapeutics·Jason M GowDeanna L Kroetz
Nov 26, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tristan M SissungWilliam D Figg
Feb 22, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kevin G Chen, Branimir I Sikic
Dec 4, 2013·Future Oncology·H Miles PrinceAmit Khot
Jul 22, 2010·Expert Review of Anticancer Therapy·Cliona GrantSusan E Bates
Nov 18, 2010·Expert Opinion on Pharmacotherapy·Nitin Jain, Olatoyosi Odenike
Jan 5, 2013·Expert Opinion on Drug Metabolism & Toxicology·Joanna FraczekVera Rogiers
Jun 28, 2011·Expert Opinion on Investigational Drugs·Erin M Bertino, Gregory A Otterson
Dec 2, 2014·Pharmacology & Therapeutics·Renata SilvaFernando Remião
Nov 27, 2015·American Journal of Hematology·Ryan A Wilcox
Feb 16, 2008·Biochemical and Biophysical Research Communications·Yong Kee KimSu-Nam Kim
Oct 24, 2007·Critical Reviews in Oncology/hematology·Pier Luigi ZinzaniLorenzo Cerroni
Jun 24, 2014·Molecular Oncology·Victoria L LuchenkoSusan E Bates
May 3, 2008·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Lena MarquardMaxwell Sehested
Oct 13, 2011·American Journal of Hematology·Ryan A Wilcox
Oct 31, 2009·British Journal of Haematology·Susan E BatesRichard L Piekarz
Jul 22, 2014·American Journal of Hematology·Ryan A Wilcox
Jun 4, 2014·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Ilaria PelusoMaura Palmery
Nov 30, 2012·Cancer Biology & Therapy·Caterina IeranoStefania Scala
Mar 30, 2013·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Régis DelatouchePhilippe Bertrand
Jul 22, 2011·American Journal of Physiology. Cell Physiology·Pedro GonçalvesFátima Martel
Jul 18, 2019·American Journal of Hematology·Alexandra C HristovRyan A Wilcox
Mar 21, 2020·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Dahea YouLauren M Aleksunes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.